Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923006 | 0.90 | CYP19A1 (0.46) | CYP19A1PPARDCYP11B1CYP11B2AAK1 | |
| Bromide SCHEMBL8124970 | 0.89 | CYP19A1 (0.45) | CYP19A1PPARDCYP11B1CYP11B2AAK1 | |
| SCHEMBL8352315 | 0.84 | CYP19A1 (0.50) | CYP19A1PPARD | |
| SCHEMBL31374633 | 0.81 | ALDH1A1 (0.52) | CYP19A1CYP24A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6644734 | 0.81 | ALDH1A1 (0.52) | CYP19A1CYP24A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2882437 | 0.77 | CYP19A1 (0.40) | CYP19A1PPARDALDH1A1 | |
| SCHEMBL7302984 | 0.77 | CYP19A1 (0.60) | CYP19A1CYP26A1CYP24A1 | |
| SCHEMBL8129792 | 0.76 | CYP19A1 (0.42) | CYP19A1PPARD | |
| SCHEMBL9855381 | 0.75 | CYP26A1 (0.60) | CYP19A1CYP26A1CYP24A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL924605 | 0.74 | HTR1A (0.43) | CYP19A1MIFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2008088936-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1015450-A1 | NOVEL PYRIDAZINE COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-07-05 | — | — | EP | disclosed |
| US-5935956-A | Pyridazine compounds | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-08-10 | — | — | US | disclosed |
| WO-1997045428-A1 | NOVEL PYRIDAZINE COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | CYP19A1 1852/4885PPARD 3430/4885CYP11B1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.